Seeking Alpha
Full index of posts »
Latest Comments
-
logicalthought on I Think That the Dollar Slide is About to Accelerate, and... That's a great story re. Canadian real estate. ...
-
Albertarocks on I Think That the Dollar Slide is About to Accelerate, and... >What I've read there is 1120 or so is a ver...
-
logicalthought on I Think That the Dollar Slide is About to Accelerate, and... >> I could be wrong, after all I got marr...
-
Northern Dancer on I Think That the Dollar Slide is About to Accelerate, and... logical, I use Elliott Wave analysis to the ext...
-
logicalthought on I Think That the Dollar Slide is About to Accelerate, and... lol... Stopped out at 1105, high (so far) at 11...
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.


















I Sold My SNTS Today Because of this Story:
Here's my back-of-the-envelope analysis, derived from stats I culled from various web sites:
Approximately 3.5 million U.S. patients are on Plavix and approximately 65% of them are also prescribed a PPI. Meanwhile, 8.7 million Americans are on PPIs. So if 65% of those on Plavix stop taking PPIs, 2.3 million patients out of 8.7 million would be lost, which would be 26%. However, SNTS's drug is actually gaining market share, so let's say it's a 20% haircut to SNTS's Zegerid (its branded PPI) sales. SNTS's drug is doing around $125 million/year, so this could be a $25 million revenue hit. As I'm valuing the company at 2x revenue + cash, I could see this as a hit to the stock price of just under $1/share. (SNTS's total run-rate revenue is around $150 million including all products. Also, there are lots of other crosswinds here, though, as competing-- although not as fast-acting-- PPIs go OTC soon, and they will probably steal some share from prescription Zegerid, but on the other hand, Schering Plough is licensed to market its own version of OTC Zegerid assuming it gets FDA approval in December, and SNTS will get a 10% royalty on that, and I think that will eventually be a $150 million drug.)
Net-net, my inclination is to reduce my current valuation of this company (assuming it wins its lawsuit) from the mid-$6s to the mid-$5s, so considering the lawsuit risk, I'm inclined to buy this back somewhere lower in the $3s, but not up here at around $4.
Hey, I could be wrong and the stock could go to $7 by February, but this is my thought process and please feel free to disagree.
As an aside, I've been continually adding to my DUSA, and it's now around a 17% position for me.
I Bought Another Little Microcap Healthcare Stock
A Blast From the Past: Stagflation (but with an ugly twist)
No positions in companies mentioned.
A Few Words About Volume (and the lack thereof)
However, in fairness, I'd like to point out that most of the climb from 2003 to 2007 took place at much lower volume levels than even the "light" levels of today. (I'm using SPY volume as a proxy for overall market volume, as I believe it's pretty accurate.) Take a look at a five-year daily SPY chart and see how many 40, 50, 60 and 70 million-share days there were then, vs. the "light" days of today of 140, 150 or 160 million shares. Perhaps this is distorted by more computer trading these days, but I'm sure there was plenty of computer trading then, too-- after all, we're just going back three, four and five years, not 30, 40 or 50. So, this is one caveat I want to throw out there for anyone (myself included) who's looking for a technical-- rather than a fundamental or news-driven-- reason for this rally to end.
Long SDS
I Think That the Dollar Slide is About to Accelerate, and...
I Got Very Short Again Today Into This Bounce